Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC – Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 38,400 shares, an increase of 58.0% from the March 31st total of 24,300 shares. Currently, 3.2% of the company’s shares are short sold. Based on an average daily volume of 49,500 shares, the short-interest ratio is currently 0.8 days.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research report on Wednesday. They set a “hold” rating for the company.
Read Our Latest Stock Report on Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Trading Down 5.6 %
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million for the quarter. As a group, equities research analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
Featured Articles
- Five stocks we like better than Cyclacel Pharmaceuticals
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MarketBeat Week in Review – 4/22 – 4/26
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the NASDAQ Stock Exchange?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.